From another article, a most profound characterization of side effects -
"Other advantages of the drug (pci-32765), are that it is given orally and has a modest side effect profile: “The paucity of side effects is extraordinary for a drug that is as active as this; indeed, the side effects seen to date in the Phase II study are what you might expect to see in the placebo arm,” enthuses Rule.
Rule - is Simon Rule, a consultant haematologist at the Derriford Hospital, Plymouth, UK
PCI-32765 is in trials in Austria, the UK and Poland.
Unlike so many other pharm stocks that need to heavily dilute to avoid bankruptcy, PCYC has no need for that due to the excellent balance sheet which has so much up front money from our partnership with Johnson & Johnson.